SMMT Summit Therapeutics Inc. Common Stock
XNAS 15.48 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SMMT
$15.48
—
Key stats
$15.48
- 52-Week Range
- $12.07 – $29.23
- YTD
- -11.62%
- IV Rank (30D)
- 81.55
- Straddle Price
- $4.85
- P/C Vol Ratio
- 0.93
- Market Cap
- $12.6B
- Open
- $15.29
- Day Range
- $15.13 – $15.70
- Volume
- 1,626,275
- Prev Close
- $15.83
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.62 |
| Cost of Equity (CAPM) | 8.25% (VRP-adj) |
| WACC | 8.23% |
| Volatility Risk Premium | +72.2pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.5B |
| Return on Equity (TTM) | -135.9% |
| Book / Price | 5.2% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $15.75 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $16.34 |
| Bollinger Width / SMA20 | 134.4% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $12B |
Peers used for multiples: AMGN, CELC, COGT, GILD, IMNM, LLY, MRK, RVMD
60-Day Conviction
16%
20-Day Fair Value
≈ by Nov 20, 2026
$15.55
α +0.5%
rank 46%
conviction
35%
40-Day Fair Value
≈ by Dec 21, 2026
$15.71
α +1.6%
rank 47%
conviction
50%
60-Day Fair Value
≈ by Jan 19, 2027
$15.53
α +0.4%
rank 38%
conviction
16%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 42.8× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 29.3× · 4 peers |
| Peer P/B | $13.37 | 28% | median 16.2× · 7 peers |
| Peer P/S | n/a | 0% | median 6.3× · 4 peers |
| Market Anchor (SMA50) | $15.75 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $15.30 | 72% | 43 strikes · skew +0.19 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $12.6B
- Employees
- 265
- List Date
- 2015-03-05
- CIK
- 0001599298
- Headquarters
- Miami, FL
- Homepage
- https://www.smmttx.com
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 34.62% | -21.99% | -29.00% | 48.48% | 17.17% | -17.35% | 5.32% |
| Feb | -2.73% | 19.65% | -52.63% | 13.50% | 3.55% | 17.99% | -0.11% |
| Mar | -11.33% | -23.44% | -3.85% | -10.97% | 0.84% | 17.11% | -5.27% |
| Apr | 3.75% | -32.91% | -27.87% | -1.26% | 28.30% | 13.42% | -2.76% |
| May | 21.62% | -7.64% | 9.40% | 84.79% | -26.17% | 8.84% | 15.14% |
| Jun | -6.16% | -24.81% | 46.78% | -11.76% | 20.06% | -7.26% | 2.81% |
| Jul | -8.49% | 6.33% | -13.22% | 32.68% | 24.39% | -9.52% | 5.36% |
| Aug | 2.84% | 20.00% | -22.49% | 21.76% | -12.45% | 4.41% | 2.35% |
| Sep | -31.18% | -8.46% | 14.72% | 73.81% | -13.34% | 19.42% | 9.16% |
| Oct | 0.98% | -9.92% | 9.60% | -7.51% | -7.71% | -7.31%* | -3.65% |
| Nov | -2.87% | -25.93% | 4.10% | -2.79% | -1.81% | -- | -5.86% |
| Dec | -45.10% | 524.91% | 22.54% | -3.49% | 1.33% | -- | 100.04% |
| Total | -52.05% | 62.14% | -59.59% | 488.57% | 20.58% | 36.72% | 82.73% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $16.29
SMA 50: $15.76
SMA 200: $16.26
Current: $15.47
EMA 12: $15.93
EMA 26: $16.12
MACD: -0.1885 | Signal: -0.1730
BEARISH
ADX (14): 17.76
RANGE
+DI: 21.82
−DI: 23.20
Momentum Oscillators
RSI (14): 45.31
NEUTRAL
Stoch %K: 32.82
Stoch %D: 29.84
Williams %R: -75.85
Volume & Volatility
BB Upper: $18.13
BB Lower: $14.46
NEUTRAL
OBV: 55,523,293
Vol SMA 20: 6,964,533
Vol ROC: -73.98%
ATR: $0.98
True Range: $0.70
HV 20: 64.1%
HV 30: 61.0%
HV 60: 68.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary BULLISH (Confidence Level: 6/10)
Key drivers:
- Technical indicators suggest a range-bound market with potential for breakout
- Options metrics indicate low volatility and bearish sentiment
- Recent news headlines are mixed, but overall sentiment is slightly negative
Primary risks:
- High beta and volatility can lead to significant price swings
- Bearish options sentiment may continue to pressure the stock
Investment thesis: SMMT's recent volatility and options market pricing suggest a potential mean reversion opportunity. The stock's high beta and range-bound technical indicators create a nuanced environment, where a bullish catalyst could trigger a breakout.
Recent news sentiment impact:
- Recent headlines have been mixed, with more negative than positive stories (Sentiment: NEUTRAL)
- Options market has priced in $3.75 move by expiration, suggesting some uncertainty
Technical Analysis
Trend Direction: Short-term: Range-bound Medium-term: Uptrend (SMA 50 above SMA 20 and price above SMA 200) Long-term: Downtrend (price below SMA 200)
Support/Resistance Levels:
- Upper Bollinger Band: $15.02
- Middle Bollinger Band: $13.50
- Lower Bollinger Band: $11.98
Momentum Signals: RSI: Neutral (47.81) MACD: Bearish (Histogram: -0.31)
Volume Analysis:
- Volume SMA 20: 4726145.78
- On-Balance Volume (OBV): 26823235.38
- Volume Rate of Change: -73.84%
News & Sentiment Analysis
Recent Headlines Summary: Negative headlines outnumbered positive ones, with a slight negative bias
Sentiment Assessment: NEUTRAL
Catalyst Identification:
- No upcoming earnings dates or major announcements scheduled
Market Narrative: Recent news sentiment has been mixed, but the options market's pricing suggests some uncertainty and potential for mean reversion.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta: 1.61)
Volatility Regime: High volatility - stock moves more than market
Options Market Signals:
- IV Rank: 20.0% (Low)
- Put/Call Volume Ratio: 1.76 (Bearish sentiment)
Downside Protection: Support levels: SMA 200, $11.98
Market Context & Positioning
Sector Performance: SMMT's sector is up 2.5% in the last quarter
Institutional Activity: Volume patterns suggest institutional interest, but not significantly above average
Correlation Analysis: Stock moves relatively independently of market (R-squared: 0.28)
Relative Valuation: Position within trading range
Key Levels & Action Items
Critical Price Levels:
- Support: SMA 200, $11.98
- Resistance: Upper Bollinger Band, $15.02
Breakout/Breakdown Levels:
- Breakout: Above $14.09 (SMA 50)
- Breakdown: Below $13.30 (EMA 12)
Time-Sensitive Catalysts:
- No upcoming earnings dates or major announcements scheduled
Risk Management: Stop-loss levels and position sizing considerations based on options market signals and volatility.
Recommendations
- Monitor the stock's price action and options market signals for potential mean reversion opportunities.
- Consider adjusting stop-loss levels based on the options market's pricing and volatility.
- Keep a close eye on the stock's sector performance and institutional activity for potential catalysts.
By following these guidelines, you'll provide a comprehensive analysis that takes into account technical indicators, options metrics, beta analysis, market data, and recent news headlines.
Generated
News
All SMMT news →
Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech. The post AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck appeared first on Investor's Business Daily .
Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
Showing 1–10 of 15
Page 1 of 2
Earnings History
12 of 16 under expected move
Avg Expected Move
14.40%
Avg Actual Move
10.32%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-01-09 | Pre-Market | 22.62% | 10.24% | 0.45x | Within |
| 2023-03-09 | Pre-Market | 16.45% | 6.58% | 0.40x | Within |
| 2023-05-11 | Pre-Market | 7.55% | 9.20% | 1.22x | Exceeded |
| 2023-08-02 | Pre-Market | 10.05% | 6.70% | 0.67x | Within |
| 2023-11-07 | Pre-Market | 13.76% | 12.16% | 0.88x | Within |
| 2024-01-08 | Pre-Market | 27.84% | 16.47% | 0.59x | Within |
| 2024-05-01 | Pre-Market | 21.88% | 19.59% | 0.90x | Within |
| 2024-08-06 | Pre-Market | 15.48% | 4.74% | 0.31x | Within |
| 2024-10-30 | Pre-Market | 7.56% | 14.57% | 1.93x | Exceeded |
| 2025-01-13 | Pre-Market | 9.10% | 1.82% | 0.20x | Within |
| 2025-05-01 | Pre-Market | 9.33% | 2.28% | 0.24x | Within |
| 2025-08-11 | After-Close | 17.70% | 9.08% | 0.51x | Within |
| 2025-10-20 | Pre-Market | 22.99% | 4.55% | 0.20x | Within |
| 2026-01-12 | Pre-Market | 9.27% | 13.41% | 1.45x | Exceeded |
| 2026-04-30 | After-Close | 8.74% | 24.91% | 2.85x | Exceeded |
| 2026-07-23 | After-Close | 10.01% | 8.81% | 0.88x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SMMT Options Activity & IV Rank
SMMT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 139.2%
7-DTE IV: —
Expected Move: $4.85
7-DTE Move: $1.82
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 348
Put Volume: 325
P/C Volume: 0.934
NEUTRAL
Call OI: 18,164
Put OI: 4,407
P/C OI: 0.243
Total OI: 22,571
ATM Options Pricing
ATM Call: $2.45
ATM Put: $2.40
Call %: 15.8%
Put %: 15.5%
Chain Summary
Chain Volume: 9,177
Chain OI: 227,952
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 52nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
52%
vs own history
GEX tilt
+0.11
OI-weighted, today
Vanna tilt
+0.26
δ-sensitivity to IV
Charm tilt
-0.53
δ-decay vs time
Charm tilt -0.53: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 73 ATM contracts, 43k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM 71.2% / Wing —
30 DTE / 10d
84%
+15.4
pts
EXTREME
ATM 123.8% / Wing 139.2%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)81.5HighOct 22
Straddle Price (30 DTE)$4.85Oct 22
Beta Analysis
Risk Metrics
Beta: 1.6871
Alpha: -20.54%
Correlation: 0.3027
R-Squared: 9.2%
Stock Volatility: 71.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SMMT
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $53.9M | #311 of 1945 | +371.5% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $34.2M | #815 of 3716 | +1760.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $25.1M | #1022 of 6285 | +290.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $0K | #4672 of 4729 | -73.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SMMT Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 761,190,222 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
18 filers$61.53M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | DIADEMA PARTNERS LP | $12.53M | 20.37% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $11.23M | 18.24% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $9.35M | 15.20% | 2026-06-30 |
| 4 | Caption Management, LLC | $4.76M | 7.73% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $4.39M | 7.14% | 2026-06-30 |
| 6 | Squarepoint Ops LLC | $3.51M | 5.70% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $2.76M | 4.48% | 2025-09-30 |
| 8 | IMC-Chicago, LLC Custodian | $2.61M | 4.23% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $2.23M | 3.63% | 2026-06-30 |
| 10 | LMR Partners LLP | $1.46M | 2.37% | 2026-06-30 |
| 11 | Affinity Asset Advisors, LLC | $1.46M | 2.37% | 2026-06-30 |
| 12 | NOMURA HOLDINGS INC | $1.44M | 2.34% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $1.13M | 1.83% | 2026-06-30 |
| 14 | UBS Group AG Custodian | $1.05M | 1.71% | 2026-06-30 |
| 15 | Persistent Asset Partners Ltd | $519.51K | 0.84% | 2026-06-30 |
| 16 | Citigroup Inc. Custodian | $437.10K | 0.71% | 2026-06-30 |
| 17 | Verition Fund Management LLC | $364.25K | 0.59% | 2026-06-30 |
| 18 | TUDOR INVESTMENT CORP ET AL | $304.51K | 0.49% | 2026-06-30 |
14 filers$52.99M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $16.16M | 30.50% | 2026-06-30 |
| 2 | LMR Partners LLP | $11.95M | 22.56% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $7.39M | 13.95% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $4.84M | 9.14% | 2026-06-30 |
| 5 | DIADEMA PARTNERS LP | $2.91M | 5.50% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $2.77M | 5.22% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $1.64M | 3.10% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $1.57M | 2.97% | 2025-09-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $1.51M | 2.86% | 2026-06-30 |
| 10 | Caption Management, LLC | $1.49M | 2.81% | 2026-06-30 |
| 11 | NOMURA HOLDINGS INC | $262.26K | 0.49% | 2026-06-30 |
| 12 | TUDOR INVESTMENT CORP ET AL | $246.23K | 0.46% | 2026-06-30 |
| 13 | MAI Capital Management | $145.70K | 0.28% | 2026-06-30 |
| 14 | Persistent Asset Partners Ltd | $81.05K | 0.15% | 2026-06-30 |
SMMT Insider Trading (Form 4)
Latest: 2026-10-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Bhaskar Anand | Chief Accounting Officer | Award (A) | +100,000 | — | EDGAR | |
| 2026-06-12 | Robert W Duggan | Co-Chief Executive Officer | Buy (P) | +3,810,000 | $13.12 | $49.99M | EDGAR |
| 2026-06-12 | Mahkam Zanganeh | Co-Chief Executive Officer | Buy (P) | +3,810,000 | $13.12 | $49.99M | EDGAR |
| 2026-06-04 | Manmeet Singh Soni | COO and CFO | Buy (P) | +50,000 | $14.45 | $722.2K | EDGAR |
| 2026-06-04 | Mahkam Zanganeh | Co-Chief Executive Officer | Buy (P) | +100,000 | $14.60 | $1.46M | EDGAR |
| 2026-06-04 | Robert W Duggan | Co-Chief Executive Officer | Buy (P) | +100,000 | $14.60 | $1.46M | EDGAR |
| 2026-01-12 | Bhaskar Anand | Chief Accounting Officer | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-01-06 | Alessandra Cesano | Director | Grant (A) | +38,219 opt | — | EDGAR | |
| 2026-01-06 | Kenneth A Clark | Director | Grant (A) | +52,796 opt | — | EDGAR | |
| 2026-01-06 | Mostafa Ronaghi | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2026-01-06 | Jeff Huber | Director | Grant (A) | +44,885 opt | — | EDGAR | |
| 2026-01-06 | Yu Xia | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2026-01-06 | Robert F. Booth | Director | Grant (A) | +42,180 opt | — | EDGAR | |
| 2026-01-06 | Robert W Duggan | Co-Chief Executive Officer | Grant (A) | +11,232 opt | — | EDGAR | |
| 2026-01-06 | Mahkam Zanganeh | Co-Chief Executive Officer | Grant (A) | +11,232 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SMMT Insider Holdings
6 insiders · @ $15.47
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Robert W Duggan | Co-Chief Executive Officer | 599,708,353 | $9.28B | $651.81M | 18 | 2026-06-12 |
| 2 | Yu Xia | Director | 32,057,147 | $495.92M | $10.00M | 4 | 2026-01-06 |
| 3 | Mahkam Zanganeh | Co-Chief Executive Officer | 25,855,474 | $399.98M | $115.43M | 23 | 2026-06-12 |
| 4 | Manmeet Singh Soni | COO and CFO | 3,098,603 | $47.94M | $5.72M | 10 | 2026-06-04 |
| 5 | Bhaskar Anand | Chief Accounting Officer | 261,047 | $4.04M | $0 | 8 | 2026-10-14 |
| 6 | Jeff Huber | Director | 6,000 | $92.8K | $0 | 4 | 2026-01-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SMMT Board & Officers
As of SEC filings through Oct 14, 2026Directors 9
- Manmeet Singh Soni · since Sep 18, 2020
- Robert W Duggan · since Sep 18, 2020
- Mahkam Zanganeh · since Nov 11, 2020
- Kenneth A Clark · since Oct 7, 2021
- Robert F. Booth · since Sep 28, 2022
- Alessandra Cesano · since Nov 15, 2022
- Yu Xia · since Jan 17, 2023
- Mostafa Ronaghi · since Apr 11, 2024
- Jeff Huber · since Jun 27, 2024
Officers 4
- Robert W Duggan · Co-Chief Executive Officer · since Sep 18, 2020
- Mahkam Zanganeh · Co-Chief Executive Officer · listed since Oct 2023
- Manmeet Singh Soni · COO and CFO · listed since Aug 2024
- Bhaskar Anand · Chief Accounting Officer · since Apr 2, 2024
10% owners 2
- Mahkam Zanganeh · listed since Jan 2025
- Robert W Duggan · listed since Jan 2024
Changes in the last 10 years (37)
| Jan 6, 2025 | Mahkam Zanganeh first listed as a 10% owner in an SEC filing |
| Aug 23, 2024 | Manmeet Singh Soni listed as COO and CFO (previously Chief Operating Officer) in SEC filings |
| Jun 27, 2024 | Jeff Huber became a director |
| Jun 12, 2024 | The company announced the departure of Ujwala Mahatme from the board in an SEC filing |
| Apr 11, 2024 | Mostafa Ronaghi became a director |
| Apr 2, 2024 | The company announced the departure of Ankur Dhingra as Chief Financial Officer in an SEC filing |
| Apr 2, 2024 | Bhaskar Anand became Chief Accounting Officer |
| Jan 4, 2024 | Robert W Duggan first listed as a 10% owner in an SEC filing |
| Oct 16, 2023 | Manmeet Singh Soni first listed as Chief Operating Officer in an SEC filing |
| Oct 16, 2023 | Mahkam Zanganeh listed as Co-Chief Executive Officer (previously Co-CEO & President) in SEC filings |
| Jan 17, 2023 | Yu Xia became a director |
| Nov 15, 2022 | Alessandra Cesano became a director |
| Sep 28, 2022 | The company announced the departure of Urte Gayko from the board in an SEC filing |
| Sep 28, 2022 | Robert F. Booth became a director |
| Aug 18, 2022 | Mahkam Zanganeh listed as Co-CEO & President (previously Chief Operating Officer) in SEC filings |
| Jun 1, 2022 | The company announced the departure of Michael Paul Donaldson as Chief Financial Officer in an SEC filing |
| May 31, 2022 | Ankur Dhingra became Chief Financial Officer |
| May 25, 2022 | Robert W Duggan no longer listed as a 10% owner in SEC filings |
| Jan 7, 2022 | The company announced the departure of Jeffrey R Maranian as VP Corporate Controller in an SEC filing |
| Nov 3, 2021 | Urte Gayko became a director |
| Oct 7, 2021 | Kenneth A Clark became a director |
| Jul 2, 2021 | Jeffrey R Maranian became VP Corporate Controller |
| Feb 26, 2021 | Luhua Wang became a director |
| Nov 24, 2020 | Mahkam Zanganeh first listed as Chief Operating Officer in an SEC filing |
| Nov 11, 2020 | Mahkam Zanganeh became a director |
| Oct 4, 2020 | Camilla Graham became Chief Clinical Affairs Officer |
| Sep 18, 2020 | Ventzislav Stefanov became an officer |
| Sep 18, 2020 | Ventzislav Stefanov became a director |
| Sep 18, 2020 | Ujwala Mahatme became a director |
| Sep 18, 2020 | Robert W Duggan became a director |
| Sep 18, 2020 | Robert W Duggan became a 10% owner |
| Sep 18, 2020 | Robert W Duggan became Co-Chief Executive Officer |
| Sep 18, 2020 | Rainer M Erdtmann became a director |
| Sep 18, 2020 | Michael Paul Donaldson became Chief Financial Officer |
| Sep 18, 2020 | Manmeet Singh Soni became a director |
| Sep 18, 2020 | Jos Houbiers became Chief Medical Officer |
| Sep 18, 2020 | David Jonathan Powell became Chief Scientific Officer |
Not reported recently (6)
- Luhua Wang · Last reported as a director in an SEC filing dated Mar 2, 2021
- Rainer M Erdtmann · Last reported as a director in an SEC filing dated Feb 23, 2021
- David Jonathan Powell · Last reported as Chief Scientific Officer in an SEC filing dated Dec 1, 2020
- Camilla Graham · Last reported as Chief Clinical Affairs Officer in an SEC filing dated Oct 7, 2020
- Jos Houbiers · Last reported as Chief Medical Officer in an SEC filing dated Sep 18, 2020
- Ventzislav Stefanov · Last reported as a director in an SEC filing dated Sep 18, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-06-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-06-03 | 0001599298-26-000049 | EDGAR |
| 2026-06-01 | 0001599298-26-000043 | EDGAR |
| 2026-04-30 | 0001599298-26-000037 | EDGAR |
| 2026-02-23 | 0001599298-26-000014 | EDGAR |
| 2026-01-29 | 0001599298-26-000006 | EDGAR |
| 2026-01-12 | 0001599298-26-000004 | EDGAR |
| 2025-11-07 | 0001599298-25-000166 | EDGAR |
| 2025-10-22 | 0001193125-25-245790 | EDGAR |
| 2025-10-20 | 0001599298-25-000156 | EDGAR |
| 2025-09-08 | 0001599298-25-000137 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-30 | 0001599298-26-000039 | EDGAR |
| 2025-10-20 | 0001599298-25-000159 | EDGAR |
| 2025-08-11 | 0001599298-25-000126 | EDGAR |
| 2025-05-01 | 0001599298-25-000089 | EDGAR |
| 2024-10-30 | 0001599298-24-000158 | EDGAR |
| 2024-08-06 | 0001599298-24-000117 | EDGAR |
| 2024-05-01 | 0001599298-24-000085 | EDGAR |
| 2023-11-07 | 0001599298-23-000098 | EDGAR |
| 2023-08-09 | 0001599298-23-000077 | EDGAR |
| 2023-05-11 | 0001599298-23-000054 | EDGAR |
ETF Holders
68 ETFs hold SMMT
25 shown · $374.20M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $86.6M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.59% | $61.0M | $10.4B | 2026-10-20 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.03% | $60.8M | — | 2026-09-30 |
| 4 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.06% | $39.5M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $30.5M | — | 2026-09-30 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.17% | $18.8M | $11.0B | 2026-10-20 |
| 7 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.07% | $12.6M | $19.3B | 2026-10-20 |
| 8 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.02% | $9.3M | $57.3B | 2026-10-20 |
| 9 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.01% | $8.2M | $126.1B | 2026-10-20 |
| 10 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.05% | $7.3M | — | 2026-05-31 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.8M | — | 2026-09-30 |
| 12 | QQQJ Invesco NASDAQ Next Gen 100 ETF | Invesco | 0.37% | $4.4M | — | 2026-10-20 |
| 13 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.01% | $3.8M | — | 2026-09-30 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $3.5M | $97.4B | 2026-10-20 |
| 15 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.03% | $3.1M | $10.9B | 2026-10-20 |
| 16 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.00% | $3.1M | — | 2026-05-31 |
| 17 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.39% | $2.5M | — | 2026-10-21 |
| 18 | CANC Tema Oncology ETF | Nport | 1.21% | $2.1M | — | 2026-05-31 |
| 19 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $2.1M | — | 2026-09-30 |
| 20 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $1.6M | — | 2026-05-31 |
| 21 | IYH iShares U.S. Healthcare ETF | iShares (BlackRock) | 0.03% | $1.5M | $4.5B | 2026-10-20 |
| 22 | SCHV Schwab U.S. Large-Cap Value ETF | Nport | 0.01% | $1.4M | — | 2026-05-31 |
| 23 | SMMD iShares Russell 2500 ETF | iShares (BlackRock) | 0.03% | $1.3M | $4.1B | 2026-10-20 |
| 24 | IWB iShares Russell 1000 ETF | iShares (BlackRock) | 0.00% | $1.3M | $49.2B | 2026-10-20 |
| 25 | IMCG iShares Morningstar Mid-Cap Growth ETF | iShares (BlackRock) | 0.03% | $1.2M | $4.1B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.11
TTM Revenue
—
TTM Net Income
$-856.12M
TTM Op. Cash Flow
$-458.43M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-215.73M | $-0.28 | $-141.12M |
| Q1 '26 | 2026-03-31 | — | $-189.42M | $-0.24 | $-122.29M |
| Q4 '25 | 2025-12-31 | — | $-219.17M | $-0.28 | $-101.94M |
| Q3 '25 | 2025-09-30 | — | $-231.79M | $-0.31 | $-93.08M |
| Q2 '25 | 2025-06-30 | — | $-565.90M | $-0.76 | $-66.74M |
| Q1 '25 | 2025-03-31 | — | $-62.91M | $-0.09 | $-61.17M |
| Q4 '24 | 2024-12-31 | — | $-61.20M | $-0.09 | $-48.67M |
| Q3 '24 | 2024-09-30 | — | $-56.25M | $-0.08 | $-30.30M |
| Q2 '24 | 2024-06-30 | — | $-60.38M | $-0.09 | $-33.00M |
| Q1 '24 | 2024-03-31 | — | $-43.47M | $-0.06 | $-30.13M |
| Q4 '23 | 2023-12-31 | — | $-36.57M | $-0.01 | $-19.46M |
| Q3 '23 | 2023-09-30 | — | $-21.27M | $-0.03 | $-14.90M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-23
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
18.69
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-135.9%
ROA
-113.8%
Div Yield
0.00%
FCF Yield
-3.89%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$11.78B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
41.16M
SI % of Float
29.72%
Days to Cover
4.84
Short Vol Ratio
74.3%
Free Float
138.49M
Float %
17.4%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14